通过降低血糖,诱导糖尿病的缓解
Gordon C Weir1, Susan Bonner-Weir1
1Joslin Diabetes Center, Harvard Medical School, Boston, MA, United States.
Frontiers in endocrinology
|July 6, 2023
概括
糖尿病的发病包括胰腺β细胞功能障碍. 降低葡萄糖毒性可以逆转β细胞功能障碍,为2型糖尿病和健康益处提供潜在的缓解.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病是一种日益严重的全球健康问题.
- 胰腺β细胞在糖尿病的发病过程中至关重要,调节胰岛素分泌.
- 胰岛素分泌的干扰和目标组织的敏感性是糖尿病发展的基础.
研究的目的:
- 为了阐明胰腺β细胞在糖尿病中的作用.
- 了解葡萄糖毒性对β细胞功能的影响.
- 探索糖尿病缓解的治疗策略.
主要方法:
- 审查当前对糖尿病中β细胞功能的理解.
- 对葡萄糖毒性的机制的分析.
- 针对葡萄糖水平的治疗方法的评估.
主要成果:
- 1型糖尿病 (T1D) 涉及自免疫性β细胞的破坏.
- 2型糖尿病 (T2D) 涉及β细胞无法满足胰岛素抵抗需求.
- 葡萄糖水平升高会引起"葡萄糖毒性",抑制胰岛素分泌.
结论:
- 糖尿病中的β细胞功能障碍与葡萄糖毒性有关.
- 降低葡萄糖水平的疗法可以逆转β细胞功能障碍.
- 通过降血糖策略,有机会实现完全或部分的2型糖尿病缓解.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
238
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
238
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Hypoglycemia and Glucagon
305
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
305


